Roginolisib clinical trials
Also written IOA-244.
How each study uses roginolisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the roginolisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 4
iOnctura (4) · Dana-Farber Cancer Institute (1) · The Lymphoma Academic Research Organisation (1) · St Vincent's Hospital, Sydney (1) · Jennifer R. Brown, MD, PhD (1)
Often tested with
Tested in the same studies.
Docetaxel (1) · Golcadomide (1) · Azacitidine (1) · Venetoclax (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test roginolisib.
- Jan 2027A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsPhase 1/2 · iOnctura
- Apr 2027Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLPhase 1/2 · Dana-Farber Cancer Institute
Studies
Open first, then newest update. How each study uses roginolisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingPhase 1/2The Lymphoma Academic Research OrganisationNCT07018752Written as roginolisib
- Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruitingPhase 1/2Dana-Farber Cancer InstituteNCT07847957Written as Roginolisib
- A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsRecruitingPhase 1/2iOncturaNCT06887803Written as Roginolisib
- Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisRecruitingPhase 1St Vincent's Hospital, SydneyNCT07203391Written as roginolisib
- Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 1/2Jennifer R. Brown, MD, PhDNCT06644183Written as Roginolisib
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingPhase 1iOncturaNCT04328844Written as IOA-244
- A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal MelanomaActive, not recruitingPhase 2iOncturaNCT06717126Written as roginolisib
- A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 1/2iOncturaNCT06879717Written as roginolisib
Codes
What other systems call roginolisib · ClinicalTrials.gg INT015290
- UNII (FDA) 6K8FC2TF54ROGINOLISIBOne source FDA
- NCI Thesaurus C203162RoginolisibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6K8FC2TF54 | ROGINOLISIB | One source FDA |
| NCI Thesaurus | C203162 | Roginolisib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.